Replies to post #78041 on Biotech Values

[exwannabe]

Re: MDCO before the US Congress

"Third, this bill would potentially benefit millions of seriously ill patients. "

The statement was made in the context of failure to protect late filers for the Hatch Waxley patent extension would cause bio's to reduce R&D.

Huh? Does he really think anyone would believe that companies will not develop drugs because of fear of counting to 60?

I'm not much in the "lawsuits for all" crowd, but this does seam fairly clear,

MDCO did get a bad break break though. If the FDA had been a few weeks late and approved after Dec 28 all would have been OK.